Effect of rhTPO and rhIL-11 on Thrombocytopenia after Chemotherapy in Leukemia.
10.19746/j.cnki.issn.1009-2137.2022.03.008
- Author:
Ji-Fei DAI
1
;
Rui-Xiang XIA
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.
2. Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China,E-mail:xrx2041@163.com.
- Publication Type:Journal Article
- Keywords:
acute leukemia;
chemotherapy;
recombinant human interleukin-11;
recombinant human thrombopoietin;
thrombocytopenia
- MeSH:
Humans;
Interleukin-11;
Leukemia, Myeloid, Acute/drug therapy*;
Platelet Count;
Recombinant Proteins/therapeutic use*;
Retrospective Studies;
Thrombocytopenia;
Thrombopoietin/therapeutic use*
- From:
Journal of Experimental Hematology
2022;30(3):711-717
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze and compare the efficacy of recombinant human thrombopoietin (rhTPO) and recombinant human interleukin-11 (rhIL-11) in the treatment of thrombocytopenia after chemotherapy in acute leukemia patients.
METHODS:180 patients with acute leukemia complicated with thrombocytopenia after chemotherapy in the First Affiliated Hospital of Anhui Medical University were analyzed retrospectively. Among them, 50 patients who treated with rhTPO and did not receive platelet transfusion were set as group A, 50 patients treated with rhTPO and receive platelet transfusion were set as group B, Forty patients treated with rhIL-11 without platelet transfusion were set as group C, Forty patients who treated with rhIL-11 and received platelet transfusion were set as group D. The duration of PLT below 20×109/L, the days it takes for PLT to recover to more than 100×109/L, and the incidence of different bleeding degrees were compared among several groups.
RESULTS:The duration of PLT<20×109/L in group A(3.72±1.14 d) was significantly shorter than that in group C(4.93±1.33 d) (P<0.001), and there was no significant difference from group B (P>0.05). The duration of PLT<20×109/L in group B(3.06±0.91 d) was significantly shorter than that in group D(4.65±0.98 d) (P<0.001), while the difference in duration of days between group C and D was not statistically significant (P>0.05). The times for PLT to recover to 100×109/L in group A(13.46±1.67 d) were significantly shorter than that in group C(16.85±2.13 d) (P<0.05), but there was no significant difference from group B (P>0.05). The time required for PLT to recover to 100×109/L in group B(13.36±1.49 d) were significantly shorter than that in group D(16.18±1.78 d) (P<0.05), while the difference in the days required for group C and group D was not statistically significant (P>0.05). The incidence of high bleeding risk in group B was significantly lower than that in group A (22% vs 44%, P<0.05), the incidence of high bleeding risk in group D was significantly lower than that in group C (32% vs 65%, P<0.05), and the incidence of high bleeding risk in group A was significantly lower than that in group C (44% vs 65%, P<0.05). The incidence of high bleeding risk in group B(22%) was lower than that in group D(32.5%), and the difference was not statistically significant (P>0.05).
CONCLUSION:In the treatment of acute leukemia patients with thrombocytopenia after chemotherapy, compared with rhIL-11, rhTPO can significantly shorten the duration for patients in a status with extremely low levels of PLT and the recovery time of PLT to normal range. In addition, PLT transfusion cannot speed up the time for patients to raise platelets to a safe range, nor can it shorten the duration of low PLT levels, but it can reduce the incidence of high bleeding risk events.
